Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Search

Volume XXXII, No. 5 - March 31, 2025

Global IVD Companies Issue Fourth Quarter 2024 Earnings

OVERALL, IN VITRO DIAGNOSTICS (IVD) COMPANIES REPORTED A MIXED BAG of financial results for the quarter ending Dec. 31, 2024, with Becton, Dickinson and Company, Abbott Laboratories, and Siemens Healthineers showing the most momentum based on recent earnings. Generally, IVD manufacturers did not experience double-digit growth or drops year over year, indicating that some stability […]

To access this post, you must purchase The Dark Report.

Global IVD Companies Issue Fourth Quarter 2024 Earnings Read More »

Role of Price Transparency During Path Contract Talks

CEO SUMMARY: Pathology groups have a much better opportunity to turn the tables on payers and other third parties during contract negotiations if they come armed with the data and other information recommended by two well-respected pathology experts. In this final installment of our four-part series, the price transparency approach is explained. Also discussed is

To access this post, you must purchase The Dark Report.

Role of Price Transparency During Path Contract Talks Read More »

Trump Signs Executive Order on Price Transparency

ON FEBRUARY 25, PRESIDENT DONALD TRUMP SIGNED AN EXECUTIVE ORDER targeted at driving price transparency requirements for hospitals and insurers. The order aims to strictly enforce a previous rule, signed during his first term, intended to provide patients with clear, accurate, and actionable healthcare pricing information. The executive order directs the federal Departments of the

To access this post, you must purchase The Dark Report.

Trump Signs Executive Order on Price Transparency Read More »

The Role of Price Transparency During Pathology Contract Talks

Pathology groups have a much better opportunity to turn the tables on payers and other third parties during contract negotiations if they come armed with the data and other information recommended by two well-respected pathology experts. In this final installment of our four-part series, the price transparency approach is explained. Also discussed is the importance

To access this post, you must purchase The Dark Report.

The Role of Price Transparency During Pathology Contract Talks Read More »

White House Is Off to a Fast Start, So Pay Attention

We already see the second term of President Donald Trump influencing clinical laboratory business operations. It’s not The Dark Report’s stance to jump on the political soapbox of whether Trump’s actions are a tragedy or a boon; let the cable TV pundits debate that. However, as with any move—business, political, or otherwise—the success or failure

To access this post, you must purchase The Dark Report.

White House Is Off to a Fast Start, So Pay Attention Read More »

COLA Summit to Address Lab Staffing Shortages

CEO SUMMARY: An upcoming gathering of COLA’s Workforce Action Alliance will focus on three staffing challenges: improving data needed to understand the current clinical laboratory workforce; promoting career paths for new professionals in the field; and identifying ways to better recognize these workers. Workforce shortages have long been a challenge for clinical laboratories, but the

To access this post, you must purchase The Dark Report.

COLA Summit to Address Lab Staffing Shortages Read More »

March 31, 2025, Intelligence: Late-Breaking Lab News

As this issue went to press, U.S. Health Secretary Robert F. Kennedy Jr. announced wide workforce reductions across several agencies that fall under the federal Department of Health and Human Services (HHS). They include the Food and Drug Administration (FDA), which will decrease by 3,500 employees; the Centers for Disease Control and Prevention (CDC), which

To access this post, you must purchase The Dark Report.

March 31, 2025, Intelligence: Late-Breaking Lab News Read More »

;